ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Bioinformatics"

  • Abstract Number: 2536 • ACR Convergence 2024

    Trans-Disease Microbial Biomarkers of Protection and Pathogenesis in Autoimmune Conditions: Results from the AMP AIM Consortium

    Kevin Bu1, Rebecca Blank2, Adam Cantor1, Alba Boix-Amoros3, Jose Scher4 and Jose Clemente1, and Accelerating Medicines Partnership and Immune-Mediated Diseases Network (AMP AIM), 1Icahn School of Medicine at Mount Sinai, New York, NY, 2NYU, New York, NY, 3Icahn School of Medicine, New York, NY, 4New York University School of Medicine, New York, NY

    Background/Purpose: Autoimmune and immune-mediated diseases (AIMDs) affect over 20 million Americans. Although AIMDs have distinct symptomatology, there is significant overlap in their treatment, suggesting overlap…
  • Abstract Number: 0127 • ACR Convergence 2024

    Unsupervised Machine Learning Improves Clinical Stratification and Prognostic Evaluation for Antiphospholipid Syndrome: A Large Cohort Study from China

    Chen Chen1, Ao Zhang2, Jianhui Cheng3, Zhongqiang Yao4, Juan Meng5, Yilu Qin6, Qingyi Lu1, Yufei Li1, Xiangjun Liu1, Tianhao Li7, Chao Hou7, Yundi Tang1, Hongjiang Liu8, Ning Xu1, Sai Dong1, Xinxin Li3, Fangmin Xu2, Jianping Guo1 and Chun Li1, 1Peking University People's Hospital, Beijing, China, 2Beijing University of Posts and Telecommunications, Beijing, China, 3State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China (People's Republic), 4Peking University Third Hospital, Beijing, China, 5Beijing Chaoyang Hospital Affiliated to Capital Medical University, Beijing, China, 6Affiliated Xinxiang Central Hospital of Xinxiang Medical University, Xinxiang, China (People's Republic), 7Peking University Health Science Center, Beijing, China, 8West China Hospital, Sichuan University, Chengdu, China (People's Republic)

    Background/Purpose: Antiphospholipid syndrome (APS) is a complex disease characterized by the presence of anti-phospholipid antibodies (aPLs). Its significant clinical heterogeneity brings clinical and therapeutical challenges.…
  • Abstract Number: 0898 • ACR Convergence 2024

    A Blood Transcriptome Signature Distinguishes Between Diverse Systemic Autoimmune Diseases and Infection

    Kleio-Maria Verrou1, Argyrios Theophilopoulos2, Nikolaos Vlachogiannis3, George Kollias4, Christoforos Nikolaou5 and Petros Sfikakis1, 1Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, 2Department of Immunology, Scripps Clinic and Research Foundation, San Diego, CA, 3Joint Academic Rheumatology Program, School of Medicine, National and Kapodistrian University of Athens. Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Zografou, Greece, 4Centre of New Biotechnologies and Precision Medicine (CNBPM), School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Institute for Bioinnovation, Biomedical Sciences Research Center “Alexander Fleming”, Vari, Greece. Department of Physiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece, Athens, Greece, 5Institute for Bioinnovation, Biomedical Sciences Research Center “Alexander Fleming”, Athens, Greece

    Background/Purpose: The most pathogenic responses against self and foreign antigens that lead to systemic autoimmune diseases and infections, respectively, overall engage similar immunologic components. Consequently, there are…
  • Abstract Number: 1787 • ACR Convergence 2024

    Linking Transcriptomic Profiles of Kidney and Blood Samples Provides Insight into Identification of Lupus Nephritis

    Andrea Daamen1, Kathryn Kingsmore2, Prathyusha Bachali3, Nan Shen4, Amrie Grammer5 and Peter Lipsky1, 1AMPEL BioSolutions, Charlottesville, VA, 2AMPEL BioSolutions, Charlottesville, 3AMPEL BioSolutions, Redmond, WA, 4Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jaiotong University School of Medicine, Shanghai, CN, Shanghai, China (People's Republic), 5AMPEL LLC, Charlottesville, VA

    Background/Purpose: Current clinical methods to diagnose and evaluate the severity of lupus nephritis (LN) rely on identification of kidney dysfunction followed by invasive kidney biopsies.…
  • Abstract Number: 2586 • ACR Convergence 2024

    Results from the Biopsy Driven Ebio Study: Entheseal Tissue Signature in Response to IL-17 Blockade in Psoriatic Arthritis

    Maria Gabriella Raimondo1, Hashem Mohammadian2, Stefano Alivernini3, Simon Rauber1, Filippo Fagni4, Giulia Corte5, Koray Tascilar2, Maria Antonietta D´Agostino6, Georg Schett7, Arnd Kleyer8 and Andreas Ramming1, 1Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, 2Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 3Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, Rome, Italy, 4Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 5Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, 6Catholic University of Sacred Heart, Rome, Italy, Rome, Italy, 7Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, 8Charité - Universittsmedizin Berlin, Erlangen, Germany

    Background/Purpose: Enthesitis is considered to be an early event in psoriatic arthritis (PsA) course, representing a hallmark feature of the disease. So far, most of…
  • Abstract Number: 0158 • ACR Convergence 2024

    Rheumatoid Arthritis Testing Patterns by Physicians and Advanced Practice Providers from a National Commercial Laboratory, 2014 – 2023

    Karis Lee1, Min Kyung Lee2, David Alfego3, Kristen Clark4 and Stanley Naides5, 1Labcorp, Orlando, FL, 2Labcorp, San Diego, CA, 3Labcorp, Carlsbad, CA, 4Labcorp, Raleigh, NC, 5Labcorp, Dana Point, CA

    Background/Purpose: With the commercialization of new diagnostic and monitoring tests for rheumatoid arthritis (RA) and an increasing number of advanced practice providers (APPs) in the…
  • Abstract Number: 0900 • ACR Convergence 2024

    Association Between Serum Urate, Gout, and Prostatic Cancer in European Male Populations: A Mendelian Randomization Study

    Sumanth Chandrupatla1, Nicholas Sumpter1, Tony Merriman2 and Jasvinder Singh3, 1University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Homewood, AL, 3Baylor College of Medicine, Birmingham, AL

    Background/Purpose: Gout and serum urate (SU) are associated with prostate cancer risk. Previous Mendelian randomization (MR) studies have shown mixed results on the causal relationship…
  • Abstract Number: 1789 • ACR Convergence 2024

    Multi-omic Profiling Identifies Pathogenic Pro-inflammatory Human Monocytes/Macrophages in Systemic Lupus Erythematosus

    Lais Osmani1, Min Shin2, Sang Jin Lee3, Helen Cai4, Won Jae Seong2, Hyoungsu Kim2, Jongjin Yoo2, Angela Mirabella2, William Bracamonte2, Mario Felix5, Jong Gyun Ahn2, Hong-Jai Park2, Juan Young6, Junghee Shin2, Serhan Unlu7, Noelle Yoo2, Edward Doherty2, Jiaye Chen2, Chenxi Li2, Gabriela Sanchez-Zuno2, Caroline Valdez4, Thuy Tran8, Mei Dong2, Sang Kim2, Christine Ko9, Sungyong You10, Jose Gomez11, Richard Bucala12 and Insoo Kang2, 1Yale, New Haven, CT, 2Yale University School of Medicine, Internal Medicine (Rheumatology, Allergy & Immunology), New Haven, CT, 3Division of Rheumatology, Kyungpook National University Hospital, Dae gu, Republic of Korea, 4Yale University School of Medicine, New Haven, CT, 5Yale, Hamden, CT, 6Yale University School of Medicine, Psychiatry, New Haven, CT, 7Cleveland Clinic, Internal Medicine, Cleveland, OH, 8Yale University School of Medicine, Internal Medicine (Medical Oncology), New Haven, CT, 9Yale University School of Medicine, Dermatology and Pathology, New Haven, CT, 10Cedars-Sinai Medical Center, Surgery and Computational Biomedicine, Los Angeles, CA, 11Yale University School of Medicine, Internal Medicine (Pulmonary, Critical Care & Sleep), New Haven, CT, 12Yale University School of Medicine, Internal Medicine (Rheumatology, Allergy & Immunology) and Pathology, New Haven, CT

    Background/Purpose: Systemic lupus erythematosus (SLE or lupus) is a clinically heterogeneous autoimmune disease, in which emerging evidence implicates the innate immune system, particularly monocytes and…
  • Abstract Number: 2629 • ACR Convergence 2024

    Deciphering Salivary Gland Inflammation in Sjögren’s Syndrome Reveals Shared and Autoantibody-Specific Immune Cell Heterogeneity

    Jun Inamo1, Masaru Takeshita2, Katsuya Suzuki2, Kazuyuki Tsunoda2, Satoshi Usuda2, Junko Kuramoto2, Tsutomu Takeuchi3 and Yuko Kaneko4, 1University of Colorado School of Medicine, Aurora, CO, 2Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 3Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, 4Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, JP, Shinjuku-ku, Tokyo, Japan

    Background/Purpose: Sjögren's syndrome (SS) is an autoimmune disease characterized by progressive immune cell-mediated destruction of the exocrine glands. SS patients have distinct clinical phenotypes based…
  • Abstract Number: 0209 • ACR Convergence 2024

    Characteristics of Ordering Providers and Patients with Positive Antinuclear Antibodies: A Pragmatic, Risk Model Study

    Emily Grace, Sarah Green, Nikol Nikolova, Ashley Suh, Ryan Moore, Hank Domenico, Allison McCoy and April Barnado, Vanderbilt University Medical Center, Nashville, TN

    Background/Purpose: Positive antinuclear antibodies (ANAs) cause diagnostic dilemmas for clinicians across specialties. We previously developed and validated a risk model to predict risk of developing…
  • Abstract Number: 0902 • ACR Convergence 2024

    Novel Role of TYK2mechanism in SLE Pathogenesis via T Cell and B Cell Pathways

    Joshua Hoffman1, Nicole Narayan2 and Mera Tilley1, 1Alumis Inc, South San Francisco, CA, 2Alumis, South San Francisco, CA

    Background/Purpose: SLE is a complex disease in need of novel therapies. Previously reported genome-wide association studies (GWAS) have identified a strong association between SLE and…
  • Abstract Number: 1791 • ACR Convergence 2024

    A Transcriptomic Lupus Activity Signature Associates with Cardiovascular Function

    Matthew Muller1, Elliot Luttrell-Williams1, Haley Rosmann2, Kelly Ruggles3, Jill Buyon4 and Jeffrey Berger1, 1NYU Langone, New York City, NY, 2NYU Grossman School of Medicine, New York, NY, 3NYU Grossman School of Medicine, Brooklyn, NY, 4New York University Grossman School of Medicine, New York, NY

    Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex autoimmune disorder associated with increased cardiovascular risk. Platelet activity is increased in SLE and may mediate, in…
  • Abstract Number: 2630 • ACR Convergence 2024

    Identification of Molecular Biomarkers for Sjögren’s Disease Stratification via a Deep Learning Foundation Model Dedicated to Immune-Mediated and Inflammatory Disease

    Aygalic Jara-Mikolajczak1, Zachary Abessera1, Martin Rethoret-Pasty1, Elisa Mazuir1, Apolline Bruley1, Wan Fai Ng2, Marta Alarcon-Riquelme3, Michele Bombardieri4, Simon Bowman5, Elena Pontarini6, Jacques-Eric Gottenberg7, Xavier Mariette8, Laurence LAIGLE9, Julien Duquesne1, Philippe Moigeon10 and Vincent Bouget11, and NECESSITY Consortium, 1Scienta Lab, Paris, France, 2Department of Rheumatology, Newcastle University, & HRB Clinical Research Facility, University College Cork, Newcastle upon Tyne, United Kingdom, 3Fundación Progreso y Salud, Andalusian Government, Granada, Spain, 4Centre for Experimental Medicine and Rheumatology, The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, 5Department of Rheumatology, University Hospital Birmingham, Birmingham, United Kingdom, 6William Harvey Research Institute, London, United Kingdom, 7Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, 8Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, 9Servier Laboratories, France, SURESNES, France, 10Servier Laboratories, France, Gif sur Yvette, France, 11Scienta Lab, Gif-sur-Yvette, France

    Background/Purpose: Sjögren’s Disease (SjD) exhibits heterogeneity in clinical manifestations and underlying biology. This heterogeneity complicates drug development, with no targeted therapy approved to date. Identifying…
  • Abstract Number: 0316 • ACR Convergence 2024

    Development and Evaluation of the Adult-onset Still’s Disease Activity Index Based on Whole RNA-seq Analysis: A Novel Approach Independent of Tocilizumab Treatment

    Mayu Magi1, Hiroto Yoshida1, Hiroya Tamai2, Kotaro Matsumoto2, Keiko Yoshimoto2, Yoshihiro Matsumoto1, Tetsuhiro Soeda1 and Yuko Kaneko2, 1Chugai Pharmaceutical Co., Ltd., Kanagawa, Japan, 2Keio University School of Medicine, Tokyo, Japan

    Background/Purpose: Tocilizumab (TCZ), an anti-IL-6 receptor antibody, has been shown to be effective in the treatment of adult-onset Still's disease (AOSD), a systemic inflammatory disease.…
  • Abstract Number: 0917 • ACR Convergence 2024

    Role of Mutual Information Profile Shifts in Assessing the Pathogenicity of Mutations on Protein Functions: The Case of Pyrin Mutations in Familial Mediterranean Fever

    Aysima Hacisuleyman1, Ahmet Gul2 and Burak Erman3, 1Department of Computational Biology, University of Lausanne, Lausanne, Switzerland, 2Division of Rheumatology, Department of Internal Medicine, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, Istanbul, Turkey, 33Chemical and Biological Engineering, Koc University, Istanbul, Turkey

    Background/Purpose: Predicting the pathogenicity of amino acid substitutions is crucial for understanding the functional consequences of genetic variations. Several computational methods frequently used so far…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 21
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology